NASDAQ:HEPA

Hepion Pharmaceuticals Stock News

etoro logo Buy HEPA
*Your capital is at risk
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that
CytoDyn’s stock is under selling pressure following a short-centric report from the notorious Citron Research.
Biogen has finished submitting its application for approval for aducanumab to the Food and Drug Administration. That submission was originally expected to be completed in early 2020.
Both of these small-cap vaccine stocks are up big in 2020.
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
- Positive CRV431 Data in Models of Acute Pulmonary Injury and SARS-CoV-2 Viral Replication - CRV431 attenuated lung inflammation and damage similar to or better than dexamethasone, including reductio
Regulatory News: Poxel (Paris:POXEL) : Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement G
Inventiva SA has filed proposed terms for a U.S. IPO of $102 million.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE